Newron Pharmaceuticals S.p.A.
NWPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $7 | $6 | $13 | $25 |
| Short-Term Investments | $3 | $6 | $9 | $10 |
| Receivables | $42 | $3 | $2 | $1 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $9 | $5 | $4 | $4 |
| Total Curr. Assets | $61 | $20 | $28 | $39 |
| Property Plant & Equip (Net) | $1 | $0 | $1 | $1 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $2 | $6 | -$1 | -$1 |
| Total NC Assets | $3 | $6 | $1 | $1 |
| Other Assets | $0 | $0 | $8 | $10 |
| Total Assets | $64 | $26 | $37 | $50 |
| Liabilities | – | – | – | – |
| Payables | $2 | $2 | $2 | $2 |
| Short-Term Debt | $14 | $22 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | -$0 | -$0 |
| Other Curr. Liab. | $7 | $4 | $3 | $2 |
| Total Curr. Liab. | $24 | $29 | $5 | $4 |
| LT Debt | $37 | $26 | $45 | $43 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $2 | $1 | -$0 | -$0 |
| Total NC Liab. | $39 | $27 | $45 | $43 |
| Other Liabilities | $0 | $0 | $1 | $1 |
| Cap. Leases | $1 | $0 | $0 | $1 |
| Total Liabilities | $62 | $56 | $51 | $47 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $12 | $0 | $0 |
| Common Stock | $4 | $4 | $4 | $4 |
| Retained Earnings | $11 | -$21 | -$23 | -$20 |
| AOCI | $0 | $0 | $5 | $15 |
| Other Equity | -$13 | -$24 | $0 | $5 |
| Total Equity | $1 | -$30 | -$14 | $3 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $64 | $26 | $37 | $50 |
| Net Debt | $44 | $42 | $32 | $18 |